Pcdhb21 Inhibitors
Pcdhb21 inhibitors are a group of chemical compounds that act to diminish the activity of the Pcdhb21 protein through various mechanisms involving distinct cellular signaling pathways. LY-294002 and Wortmannin, for instance, are inhibitors of the PI3K pathway, which is crucial for initiating several downstream cellular processes, including those related to survival, growth, and protein synthesis. Inhibition of PI3K by these compounds can lead to a reduction in Akt signaling, possibly resulting in decreased stability or expression of Pcdhb21 as a consequence of a less supportive cellular environment for its activity. Other inhibitors, such as U0126, PD98059, and PD0325901, specifically target the MEK/ERK pathway. By preventing the phosphorylation of MEK, these inhibitors consequently curtail the activation of ERK, a kinase that influences the transcription of various genes. If Pcdhb21 expression is regulated by transcription factors activated via the MEK/ERK pathway, then its expression could be indirectly reduced through the action of these inhibitors.
Further adding to the complexity of Pcdhb21 regulation are inhibitors that affect other key signaling molecules and pathways. SB203580, for example, selectively inhibits p38 MAP kinase, potentially altering the cellular response to stress and inflammatory signals, which might indirectly modulate the expression of Pcdhb21. The mTOR inhibitor Rapamycin and the JNK inhibitor SP600125 also contribute to the reduction of Pcdhb21 activity indirectly by suppressing mTOR-related signaling and AP-1-mediated transcriptional events, respectively. Additionally, kinase inhibitors such as Dasatinib, AZD0530, and Lapatinib, which target Src family kinases and EGFR/HER2, respectively, could further impact the expression of Pcdhb21 by blocking critical signaling pathways upstream of gene expression. Collectively, these inhibitors demonstrate a multifaceted approach to reducing the functional activity of Pcdhb21 through strategic interference with its associated signaling events.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A specific inhibitor of phosphoinositide 3-kinases (PI3K), LY-294002 prevents the phosphorylation and activation of downstream targets such as Akt. Since Akt can regulate a wide range of cellular processes including cell survival and growth, inhibition of this pathway could indirectly decrease the stability or expression of Pcdhb21 by promoting a less favorable environment for its expression. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A selective inhibitor of mitogen-activated protein kinases MEK1 and MEK2. By blocking MEK activity, U0126 prevents the activation of extracellular signal-regulated kinases (ERK), which could reduce the transcriptional activity of certain genes. Pcdhb21 expression might be indirectly inhibited through the reduction of transcription factors regulated by the ERK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
This compound selectively inhibits p38 MAP kinase, which is involved in the response to stress and inflammatory cytokines. Inhibition of p38 MAP kinase can alter the cellular stress response and may indirectly downregulate the expression of Pcdhb21 if it is responsive to these stress signaling pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Known as an mTOR inhibitor, Rapamycin suppresses cell growth and proliferation signals. As the mTOR pathway is key for protein synthesis and cell survival, inhibition by Rapamycin could cause a reduction in the expression levels of proteins such as Pcdhb21 through decreased translational activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A selective inhibitor of c-Jun N-terminal kinase (JNK), SP600125 prevents the transcriptional activation of genes regulated by AP-1 (transcription factor). If Pcdhb21 is controlled by AP-1, then its expression could be indirectly decreased via inhibition of JNK. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A selective inhibitor of MEK, which prevents activation of ERK. Similar to U0126, PD98059 can potentially reduce the expression level of Pcdhb21 by inhibiting the transcription factors that are activated by the ERK pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
As a potent PI3K inhibitor, Wortmannin blocks the PI3K/Akt pathway. This inhibition could lead to reduced cell survival signals, potentially diminishing the stability and expression of proteins like Pcdhb21. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $103.00 $293.00 $465.00 | 15 | |
A broad-spectrum protein kinase C (PKC) inhibitor, Gö6983 could affect the expression of Pcdhb21 by altering PKC-mediated signaling pathways that control gene transcription. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
An Src family kinase inhibitor, Dasatinib might indirectly impact Pcdhb21 expression by inhibiting signaling pathways that involve Src kinases, which could be upstream regulators of gene expression. | ||||||
Saracatinib | 379231-04-6 | sc-364607 sc-364607A | 10 mg 200 mg | $113.00 $1035.00 | 7 | |
A selective inhibitor of Src kinases, similar to Dasatinib, AZD0530 could indirectly reduce the expression of Pcdhb21 by blocking Src kinase-dependent signaling pathways that may influence gene expression. | ||||||